A trial of olaparib for ovarian cancer that has come back (MOLTO)

This trial looked at a second course of olaparib for women with ovarian cancer that had come back after having had platinum chemotherapy and olaparib. It was for women who had a gene change (mutation) in BRCA1 or BRCA2.

It was open to women whose ovarian cancer is one of the following:

• epithelial ovarian cancer

• fallopian tube cancer

• primary peritoneal cancer

These cancers are treated in the same way, so when we use the term ovarian cancer in this summary, we are referring to all 3.

The trial was open for people to join between 2017 and 2019. The team published the results in 2023.